Buforin II

General Information


DRACP ID  DRACP00262

Peptide Name   Buforin II

Sequence  TRSSRAGLQFPVGRVHRLLRK

Sequence Length  21

UniProt ID  P55897  P59890  P0DQL2  C0HJQ3  P06897  P02264  Q7ZUY3  Q96KK5  Q6GM86  P0C0S8  Q99878 

PubChem CID  Not available

Origin  Bufo Bufo Gargarizans

Type  Native peptide

Classification

  

Active ACP Antiangiogenic



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
U-937 Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia Leukemia 5% Cytotoxicity at 0.5 µg/ml MTT assay 6 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00262

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C106H184N40O26

Absent amino acids  CDEIMNWY

Common amino acids  R

Mass  279178

Pl  13.1

Basic residues  7

Acidic residues  0

Hydrophobic residues  7

Net charge  7

Boman Index  -7021

Hydrophobicity  -63.81

Aliphatic Index  88.1

Half Life 
  Mammalian: 100 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 21403917

Title  Antitumor activity of antimicrobial peptides against U937 histiocytic cell line

Doi Not available

Year  2011

Literature 2

Pubmed ID 8573171

Title  A novel antimicrobial peptide from Bufo bufo gargarizans

Doi 10.1006/bbrc.1996.0071

Year  1996

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.